Outcomes and treatment patterns for stage I human epidermal growth factor receptor 2‐positive breast cancer in the Surveillance, Epidemiology, and End Results database, 2010–2019

Abstract Background The risk of recurrence in patients with small, lymph node-negative, human epidermal growth factor receptor 2 (HER2)-positive breast cancers untreated with adjuvant chemotherapy/HER2-directed therapy is uncertain. To investigate this, the authors conducted a retrospective, population-based study of chemotherapy use and breast cancer-specific survival (BCSS) among patients with stage IA HER2-positive breast cancer. Methods… Continue reading Outcomes and treatment patterns for stage I human epidermal growth factor receptor 2‐positive breast cancer in the Surveillance, Epidemiology, and End Results database, 2010–2019

Editors’ Picks, January 2025: Evolutionary Insights Into Cancer, Impact of Nicotine Levels in E-cigarettes, and More

As winter marches on, let’s dive into the cool articles highlighted this month by the editors of the AACR journals. Grab a blanket and keep reading to learn how nicotine levels in e-cigarettes impact exposure to various toxins, why certain species are more likely to develop cancer, and results from a first-in-human trial evaluating a… Continue reading Editors’ Picks, January 2025: Evolutionary Insights Into Cancer, Impact of Nicotine Levels in E-cigarettes, and More

DNA damage response and repair gene mutations predict clinical outcomes in biliary tract cancer

Abstract Background This study aims to explore the genetic characteristics of biliary tract cancer (BTC), with a particular focus on the impact of DNA damage response and repair (DDR) genes on clinical outcomes. Methods A total of 180 patients with BTC and next-generation sequencing data were retrospectively analyzed. Clinical outcomes were compared between DDR-positive and… Continue reading DNA damage response and repair gene mutations predict clinical outcomes in biliary tract cancer

Expanding the role of CDK4/6 inhibitors in early breast cancer: insights from the NATALEE trial

Luminal breast cancer, defined by the expression of estrogen receptor (ER+) and the absence of human epidermal growth factor receptor 2 overexpression (HER2-), constitutes approximately 70% of newly diagnosed breast cancer cases.1 Despite advancements in outcomes in recent years, a recent pooled analysis by the Early Breast Cancer Trialists’ Collaborative Group revealed that the 10-year… Continue reading Expanding the role of CDK4/6 inhibitors in early breast cancer: insights from the NATALEE trial

An analysis of multilevel factor contributions to breast cancer screening inequities in an academic health system

Abstract Background Breast cancer screening (BCS) inequities are evident at national and local levels, and many health systems want to address these inequities, but may lack data about contributing factors. The objective of this study was to inform health system interventions through an exploratory analysis of potential multilevel contributors to BCS inequities using health system… Continue reading An analysis of multilevel factor contributions to breast cancer screening inequities in an academic health system

An analysis of multilevel factor contributions to breast cancer screening inequities in an academic health system

Abstract Background Breast cancer screening (BCS) inequities are evident at national and local levels, and many health systems want to address these inequities, but may lack data about contributing factors. The objective of this study was to inform health system interventions through an exploratory analysis of potential multilevel contributors to BCS inequities using health system… Continue reading An analysis of multilevel factor contributions to breast cancer screening inequities in an academic health system

Neoadjuvant anti-PD-1-based immunotherapy: evolving a new standard of care

Neoadjuvant (presurgical) anti-programmed cell death protein-1 (PD-1)-based immunotherapy as a new approach to cancer treatment has been developing on an accelerated trajectory since the seminal clinical trial results from studies in lung cancer and melanoma were published in 2018. Groundbreaking regulatory approvals in triple-negative breast cancer, non-small cell lung cancer and melanoma will certainly be… Continue reading Neoadjuvant anti-PD-1-based immunotherapy: evolving a new standard of care